Drug Profile
RES 530
Alternative Names: RES 530Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator PharmaMax
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Common cold
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Common cold in China
- 01 Aug 2016 Clinical trials in Common cold in China (unspecified route) before June 2016 (PharmaMax pipeline, August 2016)